![Julian Baker](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Julian Baker
Chairman at
MADRIGAL PHARMACEUTICALS, INC.
Net worth: 42 M $ as of 30/06/2026
Profile
Julian Charles Baker is the founder of Baker Bros.
Advisors LP, founded in 2000, where the title held is Managing Partner.
Current jobs include Chairman at Incyte Corp.
since 2025, Chairman at Denali Therapeutics, Inc. since 2025, Independent Chairman at Madrigal Pharmaceuticals, Inc. since 2023, Independent Director at ACADIA Pharmaceuticals, Inc. since 2015, Director at EveryONE Medicines, Inc., Managing Member at Baker Bros.
Advisors GP LLC, and Partner at FBB Associates.
Former jobs include Director at Neurogen Corp.
from 1999 to 2009, Independent Director at Idera Pharmaceuticals, Inc. from 2015 to 2018, Director at Trimeris, Inc. from 2004 to 2011, Lead Independent Director at Genomic Health, Inc. from 2012 to 2019, Director at Innoviva, Inc. from 1999 to 2007, Independent Director at Prelude Therapeutics, Inc. from 2021 to 2025, Director at Presidio Pharmaceuticals, Inc., Director at Alumis, Inc., Member at Credit Suisse First Boston Corp.
from 1988 to 1993, Principal at CSFB Private Equity Partners LLC, Advisory Board Member at Elm Street Advisors LLC, and Portfolio Manager at Tisch Financial Management from 1994 to 1999.
Education includes undergraduate degree from Harvard University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
INCYTE CORPORATION 0.14% | 30/06/2026 | 278,773 ( 0.14% ) | 32 M $ | 30/06/2026 |
BeiGene Ltd.
 BeiGene Ltd. Pharmaceuticals: MajorHealth Technology Develops biopharmaceutical products 0.02% | 22/05/2026 | 311,142 ( 0.02% ) | 7 M $ | 30/06/2026 |
| 29/05/2026 | 102,876 ( 0.06% ) | 3 M $ | 30/06/2026 | |
0.03% | 29/05/2026 | 14,840 ( 0.03% ) | 949 018 $ | 30/06/2026 |
| 31/03/2026 | 10,565 ( 0.01% ) | 271 732 $ | 30/06/2026 |
Julian Baker active positions
| Companies | Position | Start |
|---|---|---|
| INCYTE CORPORATION | Chairman | 26/06/2025 |
| ACADIA PHARMACEUTICALS INC. | Director/Board Member | 11/12/2015 |
| MADRIGAL PHARMACEUTICALS, INC. | Chairman | 15/06/2023 |
| DENALI THERAPEUTICS INC. | Chairman | 03/06/2025 |
Baker Bros. Advisors LP
 Baker Bros. Advisors LP Investment ManagersFinance BBA pursues a fundamentally driven approach to life sciences investing. The firm typically takes large, concentrated positions in the securities of life sciences companies with the potential for significant value creation over the long-term. They focus on public securities, but may, from time to time, recommend investments in private companies, life sciences and related healthcare intellectual property, royalty streams or other non-public investment opportunities. | Founder | 01/01/2000 |
EveryONE Medicines, Inc.
 EveryONE Medicines, Inc. Miscellaneous Commercial ServicesCommercial Services Develops precision therapeutics | Director/Board Member | - |
FBB Associates | Corporate Officer/Principal | - |
Baker Bros. Advisors GP LLC | Corporate Officer/Principal | - |
Former positions of Julian Baker
| Companies | Position | End |
|---|---|---|
| PRELUDE THERAPEUTICS INCORPORATED | Director/Board Member | 12/06/2025 |
| ░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
Training of Julian Baker
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
68
1st degree connections
21
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 21 |
|---|---|
Incyte Corp.
 Incyte Corp. Pharmaceuticals: MajorHealth Technology Engages in discovery, development and commercialization of proprietary therapeutics | Health Technology |
Neurogen Corp.
 Neurogen Corp. Pharmaceuticals: MajorHealth Technology Discovers and develops drugs | Health Technology |
Idera Pharmaceuticals, Inc.
 Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops drug candidates for oncology and rare disease indications | Health Technology |
Trimeris, Inc.
 Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics for viral diseases | Health Technology |
ACADIA Pharmaceuticals, Inc.
 ACADIA Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals drugs for treatment of central nervous system disorders | Health Technology |
Baker Bros. Advisors LP
Baker Bros. Advisors LP Investment ManagersFinance BBA pursues a fundamentally driven approach to life sciences investing. The firm typically takes large, concentrated positions in the securities of life sciences companies with the potential for significant value creation over the long-term. They focus on public securities, but may, from time to time, recommend investments in private companies, life sciences and related healthcare intellectual property, royalty streams or other non-public investment opportunities. | Finance |
Genomic Health, Inc.
 Genomic Health, Inc. Medical/Nursing ServicesHealth Services Engages in genomic-based diagnostic tests for overtreatment and optimal treatment of early stage cancer | Health Services |
Baker Bros. Advisors GP LLC | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
FBB Associates | |
Credit Suisse First Boston Corp.
 Credit Suisse First Boston Corp. Real Estate Investment TrustsFinance Real Estate Investment Trusts | Finance |
Innoviva, Inc.
 Innoviva, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that manufactures respiratory drugs | Health Technology |
CSFB Private Equity Partners LLC
 CSFB Private Equity Partners LLC Investment ManagersFinance CSFB Private Equity invests in companies located across the globe primarily in Europe, the United States, and APAC. The firm focuses on across a broad range of sectors and industries. It provides financing in the form of early stage, growth, buyout and special situation transactions. | Finance |
Presidio Pharmaceuticals, Inc.
 Presidio Pharmaceuticals, Inc. BiotechnologyHealth Technology Discovers and develops small-molecule antiviral therapeutics | Health Technology |
Elm Street Advisors LLC
 Elm Street Advisors LLC Investment ManagersFinance Elm Street Ventures invests in companies located in the United States. The firm targets companies operating across a broad range of sectors and industries. It provides financing for seed and early-stage capital requirements with an initial investment size of USD 0.5 - 2.5 million. It also makes follow-on investments. | Finance |
Denali Therapeutics, Inc.
 Denali Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops therapeutics for neurodegenerative diseases | Health Technology |
Prelude Therapeutics, Inc.
 Prelude Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops medicines targeting chromatin function to treat cancer and rare diseases | Health Technology |
Madrigal Pharmaceuticals, Inc.
 Madrigal Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops small-molecule drugs for cardiovascular, metabolic and liver diseases | Health Technology |
Tisch Financial Management | |
EveryONE Medicines, Inc.
EveryONE Medicines, Inc. Miscellaneous Commercial ServicesCommercial Services Develops precision therapeutics | Commercial Services |
Alumis, Inc.
 Alumis, Inc. Pharmaceuticals: MajorHealth Technology Engages in research and development of medicines for autoimmune disorders | Health Technology |
- Stock Market
- Insiders
- Julian Baker
